Does evidence support the use of long-acting treatment?

‌

Speakers

Prof. Christoph

Categories / tags

Related media

What are the considerations when choosing an antipsychotic?

How to guide schizophrenia patients to accept long-acting antipsychotics?

What is the optimal dose of antipsychotics?

Do the benefits of long-acting treatments outweigh the concerns?

Where do you see the biggest risk of relapse?

Balance efficacy and tolerability for optimal maintenance treatment.

Which factors need to be considered when choosing an antipsychotic?

What does recovery mean for schizophrenia patients?

How do you overcome the challenges of a missed dose?

How can we address the underusage of long-acting treatments?

What is your view on first and second generation drugs?

Who are the most vulnerable patients in the COVID-19 pandemic?

How can relapses in schizophrenia be prevented?

What are the main risks of COVID-19 for patients with schizophrenia?

Prof. David Taylor discusses the impact of COVID-19 on patients with schizophrenia.